dismiss

Clean Sweep Live Auction on Thur. March 28th. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

CT Homepage

New approach identifies lung cancer patients most likely to respond to chemotherapy Combines radiomics and CT image assessment

BSWH to install Glassbeam's CLEAN blueprint to leverage machine uptime Will include integrated CMMS software by EQ2

Machine learning reduces false positives for lung cancer in low-dose CT False positives occur at rate of 96 percent

Siemens to unveil its SOMATOM go.Top Cardiovascular Edition CT at ACC 19 Ideal for the cardiovascular outpatient setting

Hitachi unveils new CT and ultrasound solutions at ECR Standard version of SCENARIA VIEW and three new Arietta ultrasound solutions

Universal measurement approach to CT X-ray proposed by researchers 'Only a small change to existing practice is required to unify their measurements.'

Canon showcases CT image reconstruction tech and software upgrade at ECR Removing noise while preserving signals

Philips debuts Incisive CT at ECR Includes industry-first "Tube for Life" guarantee policy

Personalized cardiac test could eliminate unnecessary catheterizations Examines flow of blood with AI and CT

NIH awards $1.8 million to Magnetic Insight for neurovascular MPI Detects magnetic nanoparticle tracers, enables deep-tissue imaging

Progenics offers Curium exclusive license
to distribute its imaging agent, PyL

Progenics Pharmaceuticals selects Curium as European distributor of PyL

by John R. Fischer , Staff Reporter
Progenics Pharmaceuticals has selected Curium to be the distributor of its PSMA-targeted small molecule PET/CT imaging agent, PyL, in Europe.

The oncology company has granted an exclusive license to Curium to develop, and oversee regulatory approval and commercialization of the tracer, which is currently in Phase 3 development and designed to visualize prostate cancer.

Story Continues Below Advertisement

THE (LEADER) IN MEDICAL IMAGING TECHNOLOGY SINCE 1982. SALES-SERVICE-REPAIR

Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.



“Curium is a world-class leader in nuclear medicine and an ideal partner for PyL, with the infrastructure, commercial footprint and experience in prostate cancer to position PyL for success in Europe,” Mark Baker, CEO of Progenics, said in a statement. “This collaboration accelerates development of PyL in this important market, while we focus our internal efforts on advancing our Phase 3 CONDOR trial and laying the groundwork for commercialization in the United States.”

A nuclear medicine manufacturer, Curium recently partnered with RadioMedix to develop and commercialize 64Cu-Dotatate, a tracer with a 12-hour half-life that can be used to identify suspected neuroendocrine tumors during PET exams.

It also expanded its European footprint to 25 sites back in May with the acquisition of PET diagnostics maker, Cyclopharma. The move expanded its French network to 13 radiopharmacies.

The addition of the distribution rights for PyL to the Curium portfolio is a classic example of its initiative to continue growing and expanding its portfolio of nuclear medicine diagnostics, according to Curium CEO Renaud Dehareng.

“PyL has the potential to detect small lesions, offering significant advantages over existing products and others in development,” he said. “We look forward to leveraging our success with F-Choline in prostate cancer to advance the development and commercial uptake of this next-generation product.”

Curium is set to meet with European regulators in the first half of 2019 to determine an agreed-upon regulatory path.

Progenics is entitled to royalties on net sales.

CT Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.
ALL RIGHTS RESERVED